ASCO GU 2022 Updates: PARP Inhibitors in First-Line and Subsequent UC Settings

In quarter 1 of 2025, nogapendekin alfa inbakicept received regenerative medicine advanced therapy designation for lymphopenia.

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.

Retrospective analyses found that antihistamines added to atezolizumab yielded a 46% OS rate, a 48% CSS rate, and a 23% PFS rate in patients with metastatic urothelial carcinoma.